A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive Episode

Withdrawn before enrolling · Phase 3 · Has a placebo group

Conditions studied: Bipolar Disorder

In brief

The purpose of this study is to evaluate flexible doses (5-30 mg) of aripiprazole in patients with bipolar depression.

Key facts

Study ID

NCT00338273

Run by

Otsuka Pharmaceutical Development & Commercialization, Inc.

People needed

0

Starts

2006-12-01

Expected to finish

2007-11-01

Last updated by the study team

2013-11-08

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients
• Must sign informed consent prior to protocol-related procedures

You may not qualify if…

• Women who are pregnant, trying to become pregnant, or nursing
• Significant risk of committing suicide
• Any serious unstable medical conditions

Where it is running

• Local Institution — Durham, North Carolina, United States
• Local Institution — Ahmedabad, Gujarat, India
• Local Institution — Chennai, India
• Local Institution — Delhi, India
• Local Institution — Hyderabad, India
• Local Institution — Lucknow, India
• Local Institution — Mumbai, India
• Local Institution — Visakhapatnam, India

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.